Discounted Cash Flow (DCF) Analysis Unlevered

Tekla Healthcare Investors (HQH)

$17.27

-0.42 (-2.37%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 17.27 | undervalue

Operating Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 5.626.787.60242.92157.101,372.0511,982.73104,650.66913,962.147,982,049.82
Revenue (%)
EBITDA 121.2869.20-145.29241.20155.184,020.3835,111.81306,647.532,678,093.2923,389,014.76
EBITDA (%)
EBIT 121.2869.20-145.29241.20155.184,020.3835,111.81306,647.532,678,093.2923,389,014.76
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash 6.4601.65110.6771.57625.055,458.8547,674.66416,364.633,636,302.94
Total Cash (%)
Account Receivables 0.180.469.024.114.03364.823,186.1427,826.03243,017.422,122,382.35
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 17.27
Beta 0.832
Diluted Shares Outstanding 42.83
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt -%
Risk-Free Rate
Market Risk Premium
Cost of Equity 7.700
Total Debt -
Total Equity 739.61
Total Capital -
Debt Weighting -
Equity Weighting -
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 5.626.787.60242.92157.101,372.0511,982.73104,650.66913,962.147,982,049.82
EBITDA 121.2869.20-145.29241.20155.184,020.3835,111.81306,647.532,678,093.2923,389,014.76
EBIT 121.2869.20-145.29241.20155.184,020.3835,111.81306,647.532,678,093.2923,389,014.76
Tax Rate 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIAT 121.2869.20-145.29241.20155.184,020.3835,111.81306,647.532,678,093.2923,389,014.76
Depreciation ----------
Accounts Receivable --0.27-8.564.910.08-360.79-2,821.32-24,639.88-215,191.39-1,879,364.93
Inventories ----------
Accounts Payable ----------
Capital Expenditure ----------
UFCF 121.2868.93-153.85246.11155.253,659.5932,290.49282,007.652,462,901.9021,509,649.83
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) 21,939,842.83
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -0
Equity Value -
Shares Outstanding 42.83
Equity Value Per Share -